Effective January 1, 2020, the following specialty drugs, which are eligible for coverage under the medical benefit for AmeriHealth New Jersey members, will require precertification:

• Asceniv^TM (immune globulin intravenous, human-slra) – Intravenous/subcutaneous immune globulin
• Esperoct^® (antihemophilic factor [recombinant], glycopegylated-exei) – Hemophilia/coagulation factor
• Evenity^® (romosozumab-aqqg) – Bone-modifying agent
• Eylea^® (aflibercept) – Ophthalmic agents
• Herceptin Hylecta^TM (trastuzumab and hyaluronidase-oysk) – Cancer
• Herzuma (trastuzumab-pkrb) – Cancer
• Kanjinti^TM (trastuzumab-anns) – Cancer
• Lucentis^® (ranibizumab) – Ophthalmic agents
• Macugen (pegaptanib) – Ophthalmic agents
• Ontruzant^® (trastuzumab-dttb) – Cancer
• Polivy^TM (polatuzumab vedotin-piiq) – Cancer
• Revatio^® (sildenafil) – Pulmonary arterial hypertension
• Ruxience^TM (rituximab-pvvr) – Cancer
• Synojoynt^TM (sodium hyaluronate) – Hyaluronate acid products
• Trazimera (trastuzumab-qyyp) – Cancer
• Triluron^TM (sodium hyaluronate) – Hyaluronate acid products
• Tyvaso^® (treprostinil) – Pulmonary arterial hypertension
• Ventavis^® (iloprost) – Pulmonary arterial hypertension
• Xembify^® (immune globulin subcutaneous, human-klhw) – Intravenous/subcutaneous immune globulin
• Zirabev (bevacizumab-bvzr) – Cancer

In addition, the following drugs are currently pending approval from the U.S. Food and Drug Administration (FDA) and will require precertification for AmeriHealth New Jersey members once they receive FDA approval in 2020, or as of January 1, 2020, for any drug approved in 2019:

• abicipar – Ophthalmic agents
• brolucizumab – Ophthalmic agents
• casimersen – Duchenne muscular dystrophy
• cosyntropin depot – Endocrine/metabolic agents
• crizanlizumab – Miscellaneous therapeutic agents
• eptocog beta – Hemophilia/coagulation factors
• eptinezumab – Miscellaneous therapeutic agents
• givosiran – Miscellaneous therapeutic agents
• golodirsen – Duchenne muscular dystrophy
• isatuximab – Cancer
• Lapelga (pegfilgrastim) – Colony-stimulating factor
• lisocabtagene maraleucel – Chimeric antigen receptor therapy
• margetuximab – Cancer
• Reblozyl (luspatercept-aamt) – Miscellaneous therapeutic agents
• RVT-802 – Miscellaneous therapeutic agents
• viltolarsen – Duchenne muscular dystrophy
• Zynteglo (betibeglogene darolentivec) – Gene Therapy

Lastly, the following drugs will no longer require precertification approval from AmeriHealth New Jersey as of January 1, 2020:

• Beleodaq^® (belinostat) – Cancer
• Folotyn^TM (pralatrexate) – Cancer
• Imlygic^® (talimogene laherparepvec) – Cancer
• Istodax^® (romidepsin) – Cancer
• Monovisc^® (high molecular weight hyaluronan) – Hyaluronate acid products

Learn more

In the absence of a published medical policy on any of these newly approved drugs, all requests will be subject to review in accordance with the FDA-approved indications and AmeriHealth New Jersey-recognized compendia.

These changes are reflected in an updated precertification requirement list, which has been posted to our website .